Antibody Isotyping Assay

About Immuno Technologies

Immuno Technologies is a privately held, preclinical biotech company advancing a novel intranasal, viral-vector based vaccine for Lyme disease, branded as LymeMist™, alongside diagnostic assays. The company operates on a capital-efficient model, leveraging SBIR grant funding to de-risk its programs up to the pre-IND stage before seeking strategic licensing partnerships for commercialization. With an estimated 476,000 annual cases in the U.S., the lack of a marketed human Lyme disease vaccine presents a significant unmet medical need and commercial opportunity for ITi's lead candidate.

Therapeutic Areas